Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | AANAT | Q16613 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28875080 | 0.86 | MEN1 (0.60) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL6273998 | 0.85 | MEN1 (0.59) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL28242499 | 0.84 | HTR2A (0.64) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL9705533 | 0.84 | MEN1 (0.65) | MEN1KMT2ALMNACYP1A2PKM | |
| Nb-Acetyltryptamine SCHEMBL468850 | 0.81 | MEN1 (1.00) | MEN1KMT2ALMNACYP1A2PKM | |
| Methyl Carbamate SCHEMBL6828080 | 0.81 | MEN1 (0.61) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL678380 | 0.81 | HTR2A (0.69) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL6424923 | 0.81 | MEN1 (0.61) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL6425980 | 0.81 | MEN1 (0.61) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL6425177 | 0.81 | MEN1 (0.61) | MEN1KMT2ALMNACYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171456-A1 | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES | CAAMTECH INC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4472629-A2 | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES | Caamtech, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-112823036-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118119595-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023150547-A2 | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES | CAAMTECH, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-115348957-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115279770-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-0327426-B1 | Indolo[3,2,1-de][1,4]-oxazino[2,3,4-ij][1,5]naphthyridine derivatives, process for their preparation and intermediates, their use as medicaments and compositions containing them | ROUSSEL UCLAF (FR) | 1993-11-03 | — | — | EP | disclosed |
| EP-0327426-A1 | Indolo[3,2,1-de][1,4]-oxazino[2,3,4-ij][1,5]naphthyridine derivatives, process for their preparation and intermediates, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171456-A1 | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES | HTR3B, HTR2C, SLC18A2 | MEN1 2869/4885KMT2A 1753/4885LMNA 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.